January 27, 2020
Ono Pharmaceutical’s anti-PD-1 antibody Opdivo (nivolumab) failed to demonstrate a significant improvement in overall survival (OS), the primary endpoint of a PIII clinical study in Japan in patients with platinum-resistant advanced or recurrent ovarian cancer, the company said on January...read more